Skip to main content

Table 1 Clinical and pathological features of 8 cases with GP

From: Gliomatosis peritonei: a series of eight cases and review of the literature

case Age, y CA125 U/ml Tumor Size (cm) Surgical Procedure (1st surgery) Primary tumor Metastatic Tissue of the 1st surgery Adjuvant therapy GFAP Residual GP Outcome
1 23 420.1 18 USO, Peritonectomies, Appendectomy, omenctomy IMT, G1 GP PEB*3 NA YES Alive 16 months
2 25 98.9 22 USO, Peritonectomies, Omenctomy, lymphadenectomy MT GP, Nodal, gliomatosis NO + YES Alive 3 months
3 16 340.4 20 USO, Peritonectomies, Omenctomy, lymphadenectomy IMT, G2 GP, Nodal, gliomatosis PEB*6 + YES Alive 68 months
4 18 171.7 14 cystectomy IMT, G2 NA PEB*3 NA YES Alive 38 months
5 23 NA 11 cystectomy IMT, G2 NA NO NA YES Alive 61 months
6 22 381.1 25 USO, Peritonectomies, Omenctomy, lymphadenectomy IMT, G1 GP, Nodal, gliomatosis NO + YES Alive 60 months
7 15 673.5 23 USO, Peritonectomies, Omenctomy, lymphadenectomy LOV: IMT, G3, ROV: G1 GP PEB*2 PVB*2 PV*2 NA NO Alive 97 months
8 17 238.7 30 USO, Peritonectomies, Omenctomy, Lymphadenectomy, Appendectomy IMT, G3 GP, Nodal, gliomatosis PEB*4 NA YES Alive 144 months
  1. GFAP glial fibrillary acidic protein, GP gliomatosis peritonei, IMT immature teratoma, MT mature teratoma, NA not available, USO unilateral salpingo-oophorectomy, PEB bleomycin, etoposide, cisplatin, PVB bleomycin, vincristine,cisplatin, PV vincristine,cisplatin